Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jerini Submits Icatibant NDA; Asks FDA For Priority Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First

Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.

FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First

Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.

Jerini’s Firazyr For HAE Gets Advisory Committee Review Feb. 20

FDA’s Pulmonary-Allergy Drugs Advisory Committee is slated to review icatibant for hereditary angioedema.

Related Content

Topics

UsernamePublicRestriction

Register

PS065272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel